tbuckley/cabot-search huggingface dataset:
Editorial Board
Authors: Zuhair Ballas, Iowa City, Iowa Deputy, David Huston, Rachel Miller, New York, N Associate, Andrea Apter, Leonard Philadelphia, Nashville Bacharier, Claus Bachert, Joshua Boyce, Javier Chinen, Raif Geha, Johann Gudjonsson, Ann Arbor, Mich Kenji Kabashima, Corinne Keet, Carole Ober, David Peden, Harald Renz, Marburg Germany, Marc Rothenberg, Cincinnati Ohio, Hirohisa Saito, Stefan Vieths, Langen Germany, Stephan Weidinger, Peter Arkwright, Arthur Gelb, Los Angeles, Akio Mori, Harry Schroeder, Birmingham Ala, Jonathan Spergel, Julie Wang, Eric Brandt, Emma Guttman-Yassky, Hirohito Kita, Tanya Laidlaw
Journal: Journal of Allergy and Clinical Immunology (2021)
BTS guidelines for the insertion of a chest drain
Authors: D. Laws, E. Neville, J. Duffy
Journal: Thorax (2003)

These guidelines have been replaced by BTS Pleural Disease Guideline 2010 Superseded By BTS Pleural Disease Guideline 2010: BTS Guidelines for the Management of Pleural Disease. Thorax 2003 May; 58(Suppl 2): 1–59.
Commentaire de travail de M. E. Hagen et al., pp. 918
Journal: Endoscopy (2008)

See also: Hybrid natural orifice transluminal endoscopic surgery (NOTES) for Roux-en-Y gastric bypass: an experimental surgical study in human cadaversEndoscopy 2008; 40(11): 918-924DOI: 10.1055/s-2008-1077720
AB0030 Targeting nf-Κb signalling in b cells: a potential new treatment modality for anca-associated vasculitis
Authors: J.P. Van Hamburg, P. Tuijnenburg, B. Helder, L. van Keep, K. Wesenhagen, P. Kucharzewka, M.H. Jansen, A. Al-Soudi, P.L. Klarenbeek, H. Olsson, N. de Vries, T.W. Kuijpers, S.W. Tas
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The pivotal role of B cells in the pathogenesis autoimmune diseases such as ANCA-associated vasculitis (AAV) is well-established and further substantiated by beneficial therapeutic effects of rituximab (anti-CD20 B cell targeted therapy). However, this results in prolonged B cell depletion while long-lived plasma cells are not targeted. Thus, there is a need for novel therapeutics targeting the B-cell lineage in AAV. NF-κB signalling pathways that act downstream of various B cell surface receptors, including the B cell antigen receptor, CD40, BAFFR and TLRs, are crucially involved in B cell responses and may be suitable as novel targets. <h3>Objectives</h3> To identify whether inhibition of NF-κB signalling by novel pharmacological inhibitors is effective in targeting B cell responses in general and more specifically blocks (auto)antibody production and plasmablast differentiation in B cells from AAV patients. <h3>Methods</h3> PBMC and sorted B cells from AAV patients and healthy donors were cultured with T cell-dependent (anti-IgM +anti CD40+IL-21) and T cell-independent (CpG +IL-2) stimuli. NF-κB signalling was targeted in these cultures by small molecule inhibitors of NF-κB inducing kinase (NIK, non-canonical NF-κB signalling) and Inhibitor of κB kinase β (IKKβ, canonical NF-κB signalling). Downstream NF-κB signalling and nuclear NF-κB translocation was determined by Western blot and confocal imaging. Effects on B cell proliferation and differentiation were determined by CFSE dilution assays and flow cytometric analysis of B cell markers. (Auto)antibody production was measured by ELISA. <h3>Results</h3> In B cells of AAV patients and healthy donors, targeting of NIK and IKKβ effectively inhibited downstream non-canonical or canonical NF-κB signalling, respectively. In a B cell stimulation assay, NIK and IKKβ inhibition significantly reduced T cell-dependent (anti-IgM +anti CD40+IL-21) and T cell-independent (CpG +IL-2) B cell proliferation. In addition, B cell differentiation towards plasmablasts (CD27<sup>++</sup>/CD38<sup>+</sup>) and functional antibody production was attenuated by both NIK and IKKβ inhibitors. Interestingly, the effects of NIK inhibition appeared to be B cell-specific as T cell proliferation was largely unaffected. <h3>Conclusions</h3> These data demonstrate that inhibition of NF-κB signalling in AAV B cells results in the modulation of various B cell responses. Ongoing studies will indicate whether targeting of NF-κB signalling in B cells may be an effective novel treatment modality for AAV. <h3>Disclosure of Interest</h3> None declared
ORIGINAL ARTICLES.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Initial Therapy for Tuberculosis in the Era of Multidrug Resistance: Recommendations of the Advisory Council for the Elimination of Tuberculosis
Journal: JAMA (1993)

These recommendations update previous CDC/American Thoracic Society (ATS) recommendations for the treatment of tuberculosis (TB) among adults and children. The most notable changes are in response to the increasing prevalence of drug-resistant TB in the United States. These recommendations include the need for a) in vitro drug susceptibility testing of Mycobacterium tuberculosis isolates from all patients and reporting of these results to the health department, b) initial four-drug regiments for the treatment of TB, and c) initial directly observed therapy for persons with TB. Adherence to these recommendations will help prevent the occurrence of more cases of drug-resistant TB, reduce the occurrence of treatment failure, and reduce the transmission of TB in the United States.
Rabies
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Chinese Medical Journal vol 1, no. 1, January 1973
Authors: T. S. Cheng
Journal: JAMA (1973)

One of the most noteworthy events in the modern medical history is the recent reappearance of the<i>Chinese Medical Journal</i>, the official publication of the Chinese Medical Association in Peking.<i>The Chinese Medical Journal</i>resumed its publication as vol 1, No. 1 in January 1973 after its temporary suspension for the past few years following the Cultural Revolution. I was aware of the imminent reappearance of the<i>Chinese Medical Journal</i>as far back as last May when I visited the People's Republic of China.<sup>1</sup>At that time my Chinese colleagues told me that careful notes were being kept of all clinical studies, clinical investigations, and basic research during those years when all the journals ceased publication. The reappearance of this journal is indeed a welcome event, at a time when American interest in Chinese medicine increases by leaps and bounds following recent resumption of friendly relations between the People's
THE PNEUMONIA COMMISSION.
Journal: JAMA (1904)

Evidence that pneumonia is coming to be appreciated as one of the most serious scourges of humanity is afforded by the recent proposition of the New York health department to appoint a commission, including some of the best known internists of the country, to investigate the causes of this increased mortality. SinceThe Journalfirst called attention to the facts, some four years ago, the data then available have been vastly enlarged by more recent statistics and their deductions amply confirmed. After the question of the prevention of tuberculosis, and perhaps not yielding to that in importance, there is hardly any more important problem than this before the profession. How much of the increase of pneumonia mortality of late years is due to the grip infection, which still lingers with us, is worthy of serious study. Statistics, however, indicate that increase can not be altogether attributed to this cause. The
A Comparison of Greek and Modern Scientific Methods
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Circumferential Pneumatic Compression
Authors: W. James Gardner
Journal: JAMA (1966)

Experience with an aviation antigravity garment (G-suit)<sup>1</sup>in surgery suggested that pneumatic compression applied in similar fashion to an extremity should reduce edema. Therefore, in 1952, a double-walled, inflatable sleeve was constructed of rubberized fabric and employed in a postmastectomy case. As expected, the edema was reduced, and, in addition, it was discovered that the sleeve, when inflated, became an effective splint. Furthermore, when the sleeve was applied high on the limb after the manner of the Thomas splint, traction resulted, because elongation of the sleeve during inflation exerted counterpressure against axilla or groin. When an empty arm splint, ten inches in flat width, was inflated to 30 mm Hg, this elongating force was found to measure 11 lb, and with a 15inch leg model, 24 lb; this force, like the splinting effect, is proportional to the cross-sectional area of the inflated sleeve. These observations led to efforts to
Double Tongues
Authors: Zhaowei Meng, Jian Tan, Jie Mu, Rongxiu Zheng, Geli Liu
Journal: Clinical Nuclear Medicine (2014)

A 1-year-old Chinese boy presented with a mass at the base of his tongue with dysphagia. The distal end of the lesion could be put out of his mouth, making a "double tongue" appearance. Before surgery, serum test showed euthyroidism. Thyroid scintigraphy showed good function of the orthotopic thyroid, yet no uptake by the lesion, excluding ectopic thyroid. En bloc resection was performed. Histopathology demonstrated aberrant salivary tissues. Our case indicates that differential diagnosis between ectopic salivary tissues and ectopic thyroid should be borne in mind when treating patients with double tongues.
* A study of the prevalence of genetic polymorphisms in bile acid diarrhoea patients
Authors: S. Pattni, S. Pathmasrirengan, P. H. Dixon, C. Williamson, J. R. F. Walters
Journal: Gut (2011)

<h3>Introduction</h3> Bile acid diarrhoea (BAD) is a common cause of chronic diarrhoea and results from high concentrations of bile acids in the colon. It has recently been suggested that impaired production of fibroblast growth factor 19 (FGF19) in the ileum can result in excessive hepatic bile acid synthesis through reduced negative feedback regulation, and this, rather than malabsorption, is the cause of the diarrhoea. The reason for the reduced ileal FGF19 production remains unclear but it has been established that ileal FGF19 synthesis is markedly stimulated by bile acids binding to the farnesoid X receptor (FXR). In the liver, FGF19 acts through the FGFR4 receptor and its co-receptor Klotho β. Organic solute transporter α (OSTα) is the ileal basolateral bile acid transporter. The aim of this study was to determine the prevalence of 6 common single nucleotide polymorphisms (SNPs) in four genes involved in bile acid metabolism and FGF19 action, comparing the prevalence in patients with primary BAD, a similar number of controls with diarrhoea, and a larger numbers of healthy controls. <h3>Methods</h3> Two common SNPs (rs948992 and rs1789170) in the FGF19 gene were analysed as well as 2 SNPs (M173T, rs61755050 and −1g&gt;t, rs56163822) in the FXR gene. Mutations in FXR are implicated in patients with obstetric cholestasis and have been shown to reduce function and translation efficiency of FXR. A SNP in Klotho β (rs17618244) has been associated with colonic transit in IBS-D patients. A further SNP in the OSTα gene (rs939885) was also studied. Genomic DNA was extracted from 92 primary BAD patients diagnosed on the basis of an abnormal (&lt;15%) SeHCAT test and 75 diarrhoea controls. The frequencies of some of these SNPs in our local healthy population has been previous reported. Genotyping of the SNPs was performed using Taqman 59 allelic discrimination assays. <h3>Results</h3> Polymorphisms in all the genes studied were detectable in controls and in cases. No significant differences in the genotypes and allele frequencies were found in the Caucasian cohorts in the control and primary BAD groups (p &gt; 0.1). Further analysis of patients of different ethnic origin again did not show significant differences in the allele frequencies. <h3>Conclusion</h3> Major differences in the frequency of genetic polymorphisms in four candidate genes involved with FGF19 and bile acid metabolism are unlikely to be associated with primary BAD. However, the SNPs identified may contribute small effects, with a combination of SNPs in several genes producing a cumulative effect. Larger numbers of cases are required to define specific interactions or minor effects. At present the cause of the reduced FGF19 action in BAD remains uncertain.
John Collins Warren (1778-1856), early surgeon of Boston
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In this issue
Authors: Peter Kirkpatrick Senior, Alexandra Flemming, Charlotte Harrison, Sarah Crunkhorn, Monica Hoyos, Asher Mullard Assistant, Man Tse, Mariam Faruqi, Susanne Harris, Catriona Rodwell, Matthew Smyllie, Isabel Woodman, Lucie Wootton, Senior Editorial Assistants, Laura Corns, Ella Lines, Judith Shadwell, Simon Fenwick Senior, Art Editors, Kirsten Lee, Patrick Morgan, Vicky Summersby, Natalie Smith, Melanie Brazil
Journal: Nature Reviews Drug Discovery (2013)
Timely toxicology.
Authors: J F Medlin
Journal: Environmental Health Perspectives (1999)

The ToxChip, a DNA microarray chip, allows the monitoring of the expression levels of thousands of different genes at a time, thereby condensing months of painstaking laboratory tasks into a day's work. For toxicology researchers in particular, this tool is important because it promises a more effective way to identify environmental hazards and their effects on DNA. The ToxChip, developed by NIEHS scientists J. Carl Barrett, Cynthia Afshari, and Emile F. Nuwaysir, could transform the way toxicologists approach environmental problems.
The Quality Oncology Practice Initiative program: Experience in Spain.
Authors: Rafael Lopez, Antonio Anton, Enrique Aranda, Alfredo Carrato, Manuel Constenla, Juan Jesús Cruz, Eduardo Díaz Rubio, Margarita Feyjoo, Jesús García Foncillas, Pedro Gascon, Vicente Guillem, Ilse Lugo, Carlos Camps
Journal: Journal of Clinical Oncology (2018)

310 Background: Patient care quality is a discipline with enormous relevance in today’s healthcare. Quality Oncology Practice Initiative (QOPI) is a referral worldwide in quality for oncology practices. ECO Foundation is a collaboration of experts representing the major Spanish hospitals involved in the treatment of cancer patients. ECO reached an agreement with QOPI to involve Spanish hospitals in the QOPI program. Methods: Six rounds of data collection have taken place (Fall 2015 to Round 1 2018). Practices had to register online and submit data into the QOPI platform, and ECO Foundation offered all centers the necessary support. 17 Spanish hospitals have participated in the six rounds, and 7 of them have repeated participation. Core and Lung Cancer modules were completed. Results: During the six rounds, 1877 charts were submitted by the Spanish practices. In most of the rounds, the highest scores were: Pathology report confirming malignancy, Number of chemotherapy cycles documented, Patient consent for chemotherapy and 5 measures of the Lung Cancer module. The lowest scores were: Chemotherapy treatment summary provided to patient within 3 months of chemotherapy end, Chemotherapy treatment summary provided or communicated to practitioner(s) within 3 months of chemotherapy end, Smoking/tobacco use cessation counselling recommended to smokers/tobacco users in past year and Tobacco cessation counselling administered or patient referred in past year. The percentage of participating practices that presented results higher than 70% was successively 64%, 50%, 75% and 100% in the last three rounds. For the 7 hospitals that repeated participation, 3 reported an improvement of their global scores. Regarding QOPI Certification, three Spanish hospitals received this accreditation in September 2017 and one in June 2018. Conclusions: These preliminary results are a good starting point for the continued implementation of the QOPI program in Spain, thus providing a well-structured approach to analyze cancer care. ECO Foundation will continue pursuing excellence and quality with further activities like the QOPI Certification program and Quality Training Program, these being performed for the first time in Spain in 2017 and 2018 respectively.
International Course in Immuno-Biotechnology
Journal: JNCI Journal of the National Cancer Institute (1984)

International Course in Immuno-Biotechnology Get access JNCI: Journal of the National Cancer Institute, Volume 73, Issue 6, December 1984, Page 1491, https://doi.org/10.1093/jnci/73.6.1491-c Published: 01 December 1984
Third Biennial Medical Oncology Review Course
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Third Biennial Medical Oncology Review Course Get access JNCI: Journal of the National Cancer Institute, Volume 59, Issue 1, July 1977, Page 295, https://doi.org/10.1093/jnci/59.1.295-a Published: 01 July 1977
Splenectomy, steroids, and dextran 70 in thrombotic thrombocytopenic purpura
Authors: J. Cuttner
Journal: JAMA (1974)

Splenectomy was performed on six patients with thrombotic thrombocytopenic purpura as soon as the diagnosis was established. This procedure was followed by therapy with corticosteroids and dextran 70. Five of six patients are alive four months to four years after diagnosis. Since other means of therapy have resulted, at best, in 31 long-term survivors in more than 300 patients, we believe splenectomy, concomitant therapy with dextran 70 for two weeks, and corticosteroids in gradually decreasing doses for several months show great promise.
<i>Mental Diseases: A Public Health Problem.</i>By James V. May, M. D., Superintendent, Boston State Hospital, Boston, Mass., etc. With a Preface by Thomas W. Salmon, M. D., Professor of Psychiatry, Columbia University; Medical Advisor to the National Committee for Mental Hygiene, New York. (<i>Boston: Richard G. Badger, 1922.</i>)
Journal: American Journal of Psychiatry (1923)
Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population
Authors: Ruth Frikke-Schmidt, Børge G. Nordestgaard, Gorm B. Jensen, Anne Tybjærg-Hansen
Journal: Journal of Clinical Investigation (2004)

Homozygosity for mutations in ABC transporter A1 (ABCA1) causes Tangier disease, a rare HDL-deficiency syndrome. Whether heterozygosity for genetic variation in ABCA1 also contributes to HDL cholesterol (HDL-C) levels in the general population is presently unclear. We determined whether mutations or single-nucleotide polymorphisms (SNPs) in ABCA1 were overrepresented in individuals with the lowest 1% (n = 95) or highest 1% (n = 95) HDL-C levels in the general population by screening the core promoter and coding region of ABCA1. For all nonsynonymous SNPs identified, we determined the effect of genotype on lipid traits in 9,259 individuals from the general population. Heterozygosity for ABCA1 mutations was identified in 10% of individuals with low HDL-C only. Three of 6 nonsynonymous SNPs (V771M, V825I, and R1587K) were associated with increases or decreases in HDL-C in women in the general population and some with consistent trends in men, determined as isolated single-site effects varying only at the relevant SNP. Finally, these results were consistent over time. In conclusion, we show that at least 10% of individuals with low HDL-C in the general population are heterozygous for mutations in ABCA1 and that both mutations and SNPs in ABCA1 contribute to HDL-C levels in the general population.